Intra Cellular Buy or Sell Recommendation

Macroaxis provides Intra Cellular Therapies Inc buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Intra Cellular positions. The advice algorithm takes into account all of Intra Cellular Therapies Inc available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Intra Cellular buy-and-hold prospective. Please also check Intra Cellular Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus

Time Horizon

Risk Tolerance

Execute Advice
Intra Cellular Therapies Inc -- USA Stock  

USD 23.98  0.99  3.96%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Intra Cellular Therapies Inc is 'Cautious Hold'.
For the selected time horizon Intra Cellular Therapies Inc has a mean deviation of 3.56, semi deviation of 2.5, standard deviation of 5.46, variance of 29.77, downside variance of 9.69 and semi variance of 6.26
Macroaxis buy or sell recommendations module can be used to complement current analysts and expert consensus on Intra Cellular Therapies Inc. Our buy, hold, or sell recommendation engine utilizes analyzes the firm potential to grow using all fundamental data market data available at the time. To make sure Intra Cellular Therapies Inc is not overpriced, please check out all Intra Cellular fundamentals including its Net Income, Earnings Per Share, Current Liabilities, as well as the relationship between Current Ratio and Total Asset . Given that Intra Cellular Thera has Price to Earning of 6.56 times, we strongly advise you confirm Intra Cellular Thera market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Returns Distribution Density

Mean Return1.15Value At Risk4.53
Potential Upside5.68Standard Deviation5.46
 Return Density 

Intra Cellular Greeks

Alpha over DOW
Beta against DOW=0.15
Overall volatility
Information ratio =0.22

Intra Cellular Volatility Alert

Intra Cellular Therapies Inc shows above average downside volatility of 3.11 for selected time horizon. We advise investors to further inspect Intra Cellular Therapies Inc to make sure all market timing and asset allocation strategies are consistent with estimation about Intra Cellular future alpha.
 Better Than Average     
 Worse Than Average Compare Intra Cellular to competition
FundamentalsIntra CellularPeer Average
Return On Equity(23.56) % (15.17) %
Return On Asset(14.94) % (15.64) %
Current Valuation846.91 M152.14 B
Shares Outstanding54.68 M1.43 B
Shares Owned by Insiders12.22 % 6.91 %
Shares Owned by Institutions78.96 % 18.37 %
Number of Shares Shorted5.09 M3.24 M
Price to Earning6.56 times40.69 times
Price to Book2.88 times14.44 times
Revenue245.84 K9.85 B
Gross Profit245.84 K21.75 B
EBITDA(102.63 M)1.41 B
Net Income(97.77 M)517.71 M
Cash and Equivalents464.33 M3.89 B
Cash per Share8.49 times5.17 times
Debt to Equity0.31 % 0.72 %
Current Ratio33.02 times3.30 times
Book Value Per Share8.32 times13.64 times
Cash Flow from Operations(80.49 M)1.25 B
Short Ratio11.24 times2.09 times
Earnings Per Share2.12 times2.30 times
Number of Employees4910.67 K
Market Capitalization1.31 B29.78 B
Total Asset542.57 M126.86 B
Retained Earnings(193.05 M)38.24 B
Working Capital401.13 M3.58 B
Current Asset541.82 M36.8 B
Current Liabilities140.69 M33.34 B
Cautious Hold

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

   Intra Cellular exotic insider transaction detected [view details]
Risk Adjusted Performance0.2432
Market Risk Adjusted Performance7.82
Mean Deviation3.56
Semi Deviation2.5
Downside Deviation3.11
Coefficient Of Variation474.6
Standard Deviation5.46
Information Ratio0.2241
Jensen Alpha1.13
Total Risk Alpha1.55
Sortino Ratio0.3928
Treynor Ratio7.83
Maximum Drawdown22.88
Value At Risk4.53
Potential Upside5.68
Downside Variance9.69
Semi Variance6.26
Expected Short fall4.93

Current Valuation

Intra Cellular Current Valuation Analysis
Intra Cellular Therapies Inc is considered the number one company in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Biotechnology industry is currently estimated at about 1.45 Billion. Intra Cellular totals roughly 846.91 Million in current valuation claiming about 59% of stocks in Biotechnology industry.